Searching across hundreds of databases
Are you sure you want to leave this community? Leaving the community will revoke any permissions you have been granted in this community.
Integrated Clinical Trials is a virtual database currently indexing clinical trials from: EU Clinical Trials Register and ClinicalTrials.gov.
(last updated: Nov 28, 2022)
Clinical Trials Information| Database | Title | Recruitment | Conditions | Intervention | Sponsored By | Gender | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|
Clinicaltrials.gov | Studying Genes for Barrett's Esophagus in Brothers and Sisters | Unknown status | Esophageal Cancer, Precancerous Condition | Genetic, Genetic, Other, Other, Procedure - comparative genomic hybridization, genetic linkage analysis, laboratory biomarker analysis, questionnaire administration, study of high risk factors | Medical Research Council, Other | N/A - N/A | Observational | RATIONALE: Learning about how often heartburn and other risk factors occur in brothers and sisters and other family members of patients with Barrett's esophagus may help identify other individuals at risk and identify genes for Barrett's esophagus. PURPOSE: This clinical trial is studying genes for Barrett's esophagus in brothers and sisters. | |||
|
Clinicaltrials.gov | Identifying Gene Mutations in Patients With Melanoma and in Families With a History of Hereditary Melanoma | Unknown status | Hereditary Multiple Melanoma, Melanoma (Skin) | Genetic, Genetic, Genetic, Genetic, Other, Procedure, Procedure - gene expression analysis, microarray analysis, molecular genetic technique, mutation analysis, laboratory biomarker analysis, mutation carrier screening, study of high risk factors | Leeds Cancer Centre at St. James's University Hospital, Other | N/A - N/A | Observational | RATIONALE: Identifying gene mutations and other risk factors in patients with melanoma and in families with a history of hereditary melanoma may help doctors identify persons at risk for melanoma and other types of cancer. It may also help the study of cancer in the future. PURPOSE: This clinical trial is studying gene mutations in patients with melanoma and in families with a history of hereditary melanoma. | |||
|
Clinicaltrials.gov | Thalidomide in Treating Patients With Recurrent or Persistent Endometrial Cancer | Completed | Endometrial Adenoacanthoma, Endometrial Adenocarcinoma, Endometrial Adenosquamous Cell Carcinoma, Endometrial Clear Cell Carcinoma, Endometrial Papillary Serous Carcinoma, Recurrent Endometrial Carcinoma | Drug, Other - thalidomide, laboratory biomarker analysis | National Cancer Institute (NCI), NIH | Female | N/A - N/A | Phase 2 | Interventional | Phase II trial to study the effectiveness of thalidomide in treating patients who have recurrent or persistent endometrial cancer. Thalidomide may stop the growth of cancer by stopping blood flow to the tumor | |
|
Clinicaltrials.gov | Imatinib Mesylate in Treating Patients With Stage IV Colorectal Cancer | Completed | Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage IV Colon Cancer, Stage IV Rectal Cancer | Drug, Other - imatinib mesylate, laboratory biomarker analysis | National Cancer Institute (NCI), NIH | N/A - N/A | Phase 2 | Interventional | Phase II trial to study the effectiveness of imatinib mesylate in treating patients who have stage IV colorectal cancer. Imatinib mesylate may interfere with the growth of tumor cells by blocking certain enzymes necessary for cancer cell growth | ||
Clinicaltrials.gov | Tamoxifen Compared With Thalidomide in Treating Women With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | Completed | Fallopian Tube Cancer, Primary Peritoneal Cavity Cancer, Recurrent Ovarian Epithelial Cancer, Stage III Ovarian Epithelial Cancer, Stage IV Ovarian Epithelial Cancer | Drug, Drug, Other - tamoxifen citrate, thalidomide, laboratory biomarker analysis | National Cancer Institute (NCI), Gynecologic Oncology Group, NIH, Other | Female | N/A - N/A | Phase 3 | Interventional | Randomized phase III trial to compare the effectiveness of tamoxifen with that of thalidomide in treating women who have recurrent ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cancer. Estrogen can stimulate the growth of some types of cancer cells. Hormone therapy using tamoxifen may fight cancer by blocking the uptake of estrogen. Thalidomide may stop the growth of cancer by stopping blood flow to the tumor. It is not yet known whether thalidomide is more effective than tamoxifen in treating ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cancer. | |
|
Clinicaltrials.gov | Fenretinide in Treating Patients With Recurrent or Metastatic Ovarian Epithelial or Primary Peritoneal Cancer | Completed | Recurrent Ovarian Epithelial Cancer, Recurrent Primary Peritoneal Cavity Cancer, Stage IV Ovarian Epithelial Cancer, Stage IV Primary Peritoneal Cavity Cancer | Drug, Other, Other - fenretinide, laboratory biomarker analysis, pharmacological study | National Cancer Institute (NCI), NIH | Female | N/A - N/A | Phase 2 | Interventional | Phase II trial to study the effectiveness of fenretinide in treating patients who have recurrent or metastatic ovarian epithelial or primary peritoneal cancer. Drugs used in chemotherapy, such as fenretinide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing | |
|
Clinicaltrials.gov | Biomarkers in Stored Tumor Samples From Younger Patients With Liver Cancer | Withdrawn | Liver Cancer | Genetic, Genetic, Genetic, Genetic, Genetic, Other, Other, Other, Other - comparative genomic hybridization, molecular genetic technique, mutation analysis, polymerase chain reaction, proteomic profiling, immunohistochemistry staining method, laboratory biomarker analysis, mass spectrometry, medical chart review | Vanderbilt-Ingram Cancer Center, National Cancer Institute (NCI), Other, NIH | N/A - N/A | Observational | RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. PURPOSE: This laboratory study is looking at biomarkers in stored tumor samples from younger patients with liver cancer. | |||
|
Clinicaltrials.gov | GM-CSF Before Surgery in Treating Patients With Localized Prostate Cancer | Completed | Prostate Cancer | Biological, Other, Other, Other, Procedure, Procedure - sargramostim, immunohistochemistry staining method, immunological diagnostic method, laboratory biomarker analysis, conventional surgery, neoadjuvant therapy | University of California, San Francisco, National Cancer Institute (NCI), Other, NIH | Male | N/A - N/A | Phase 1 | Interventional | RATIONALE: Colony-stimulating factors, such as GM-CSF, may help the body build an effective immune response to kill tumor cells. Giving GM-CSF before surgery may be an effective treatment for localized prostate cancer. PURPOSE: This clinical trial is studying how well giving GM-CSF before surgery works in treating patients with localized prostate cancer. | |
|
Clinicaltrials.gov | Studying RNA in Samples From Younger Patients With T-Cell Acute Lymphoblastic Leukemia | Completed | Leukemia | Genetic, Genetic, Other - RNA analysis, proteomic profiling, laboratory biomarker analysis | Children's Oncology Group, National Cancer Institute (NCI), Other, NIH | N/A - N/A | Observational | RATIONALE: Studying samples of blood and tissue from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer PURPOSE: This laboratory study is looking into RNA in samples from younger patients with T-cell (T) acute lymphoblastic leukemia (ALL). | |||
|
Clinicaltrials.gov | Broxuridine Plus Surgery in Treating Patients With Stage I or Stage II Prostate Cancer | Completed | Stage I Prostate Cancer, Stage IIA Prostate Cancer, Stage IIB Prostate Cancer | Drug, Procedure, Other - bromodeoxyuridine, conventional surgery, laboratory biomarker analysis | National Cancer Institute (NCI), NIH | Male | N/A - N/A | Phase 2 | Interventional | Phase II trial to study the effectiveness of broxuridine in treating patients who are undergoing surgery for stage I or stage II prostate cancer. Broxuridine may help doctors determine the rate of growth of prostate tumors and help them plan effective treatment | |
|
Clinicaltrials.gov | Imatinib Mesylate and Decitabine in Treating Patients With Chronic Myelogenous Leukemia | Completed | Accelerated Phase Chronic Myelogenous Leukemia, Blastic Phase Chronic Myelogenous Leukemia, Childhood Chronic Myelogenous Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Relapsing Chronic Myelogenous Leukemia | Drug, Drug, Other - imatinib mesylate, decitabine, laboratory biomarker analysis | National Cancer Institute (NCI), NIH | N/A - N/A | Phase 2 | Interventional | This phase II trial is studying how well giving imatinib mesylate together with decitabine works in treating patients with accelerated or blast phase chronic myelogenous leukemia. Imatinib mesylate may stop the growth of cancer cells by blocking the enzymes necessary for cancer cell growth. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Giving imatinib mesylate together with decitabine may kill more cancer cells | ||
|
Clinicaltrials.gov | Gefitinib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer | Completed | Bronchoalveolar Cell Lung Cancer, Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer | Drug, Other - gefitinib, laboratory biomarker analysis | National Cancer Institute (NCI), NIH | N/A - N/A | Phase 2 | Interventional | Phase II trial to study the effectiveness of gefitinib in treating patients who have stage IIIB or stage IV non-small cell lung cancer. Biological therapies such as gefitinib may interfere with the growth of the tumor cells and slow the growth of non-small cell lung cancer | ||
|
Clinicaltrials.gov | Trastuzumab and Combination Chemotherapy in Treating Patients With Locally Recurrent or Metastatic Urinary Tract Cancer | Completed | Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter, Recurrent Bladder Cancer, Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter, Squamous Cell Carcinoma of the Bladder, Stage IV Bladder Cancer, Transitional Cell Carcinoma of the Bladder | Biological, Drug, Drug, Drug, Other - trastuzumab, paclitaxel, carboplatin, gemcitabine hydrochloride, laboratory biomarker analysis | National Cancer Institute (NCI), NIH | N/A - N/A | Phase 2 | Interventional | Phase II trial to study the effectiveness of combining trastuzumab with combination chemotherapy in treating patients who have locally recurrent or metastatic urinary tract cancer. Monoclonal antibodies such as trastuzumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining monoclonal antibody therapy with combination chemotherapy may kill more tumor cells | ||
|
Clinicaltrials.gov | Studying Tissue and Blood Samples From Patients With Acute Myeloid Leukemia | Active, not recruiting | Leukemia | Genetic, Genetic, Genetic, Genetic, Genetic, Genetic, Other, Other - DNA analysis, DNA methylation analysis, gene expression analysis, mutation analysis, polymerase chain reaction, reverse transcriptase-polymerase chain reaction, high performance liquid chromatography, laboratory biomarker analysis | Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), Other, NIH | N/A - N/A | Observational | RATIONALE: Studying samples of tissue and blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. PURPOSE: This research study is looking at tissue and blood samples from patients with acute myeloid leukemia. | |||
|
Clinicaltrials.gov | Immune Response in Peripheral Blood of Patients With Colon Cancer | Completed | Colorectal Cancer | Other, Other - immunoenzyme technique, laboratory biomarker analysis | University of Arizona, National Cancer Institute (NCI), Other, NIH | N/A - N/A | Observational | RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about changes that may occur in the immune system that may help kill cancer cells. PURPOSE: This laboratory study is looking at anticancer immune responses in the peripheral blood of patients with colon cancer. | |||
|
Clinicaltrials.gov | SWOG-9023, DNA Analysis of Tumor Tissue From Patients With Metastatic Kidney Cancer | Completed | Kidney Cancer | Genetic, Genetic, Genetic, Genetic, Other, Other - DNA ploidy analysis, DNA stability analysis, chromosomal translocation analysis, cytogenetic analysis, flow cytometry, laboratory biomarker analysis | Southwest Oncology Group, National Cancer Institute (NCI), Other, NIH | N/A - N/A | Observational | RATIONALE: DNA analysis of tumor tissue may help doctors predict how well patients will respond to treatment. PURPOSE: This laboratory study is analyzing the DNA in tumor tissue from patients with metastatic kidney cancer. | |||
|
Clinicaltrials.gov | Studying Biomarkers in Patients With Pancreatic Cancer | Completed | Pancreatic Cancer | Genetic, Other - protein analysis, laboratory biomarker analysis | Vanderbilt-Ingram Cancer Center, National Cancer Institute (NCI), Other, NIH | N/A - N/A | Observational | RATIONALE: Studying samples of tissue in the laboratory from patients with cancer may help doctors identify and learn more about biomarkers related to cancer. It may also help doctors predict how patients will respond to treatment. PURPOSE: This research study is studying biomarkers in patients with pancreatic cancer. | |||
|
Clinicaltrials.gov | Blood Levels of Tumor Cells in Predicting Response in Patients Receiving First-Line Chemotherapy for Stage IV Breast Cancer | Completed | Breast Cancer | Genetic, Other, Other - fluorescence in situ hybridization, immunologic technique, laboratory biomarker analysis | Institut Curie, Other | N/A - N/A | Observational | RATIONALE: Measuring blood levels of tumor cells in patients with breast cancer may help doctors predict how patients will respond to treatment. PURPOSE: This laboratory study is looking at blood levels of tumor cells in predicting response in patients receiving first-line chemotherapy for stage IV breast cancer. | |||
|
Clinicaltrials.gov | Tumor Tissue, Blood Samples, and Family History in Predicting Tumor Development and Response to Treatment in Young Patients With Low-Grade Glioma | Unknown status | Brain and Central Nervous System Tumors | Other, Other, Other - biologic sample preservation procedure, laboratory biomarker analysis, questionnaire administration | Children's Cancer and Leukaemia Group, Other | N/A - N/A | Observational | RATIONALE: Studying samples of tumor tissue and blood in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors understand why low-grade gliomas develop in young patients and predict how they will respond to treatment. PURPOSE: This clinical trial is studying tumor tissue, blood samples, and family history in predicting tumor development and response to treatment in young patients with low-grade glioma. | |||
|
Clinicaltrials.gov | Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-cell Lymphoma | Completed | B-cell Adult Acute Lymphoblastic Leukemia, B-cell Childhood Acute Lymphoblastic Leukemia, B-cell Chronic Lymphocytic Leukemia, Childhood Burkitt Lymphoma, Childhood Diffuse Large Cell Lymphoma, Childhood Immunoblastic Large Cell Lymphoma, Cutaneous B-cell Non-Hodgkin Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Intraocular Lymphoma, Nodal Marginal Zone B-cell Lymphoma, Post-transplant Lymphoproliferative Disorder, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Grade III Lymphomatoid Granulomatosis, Recurrent Childhood Large Cell Lymphoma, Recurrent Childhood Lymphoblastic Lymphoma, Recurrent Childhood Small Noncleaved Cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Small Lymphocytic Lymphoma, Recurrent/Refractory Childhood Hodgkin Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Hairy Cell Leukemia, Small Intestine Lymphoma, Splenic Marginal Zone Lymphoma, Testicular Lymphoma, Waldenström Macroglobulinemia | Biological, Procedure, Procedure, Other, Other - rituximab, peripheral blood stem cell transplantation, nonmyeloablative allogeneic hematopoietic stem cell transplantation, pharmacological study, laboratory biomarker analysis | Fred Hutchinson Cancer Research Center, American Cancer Society, Inc., National Cancer Institute (NCI), Other, Other, NIH | N/A - N/A | Phase 2 | Interventional | This phase II trial studies giving rituximab before and after a donor peripheral blood stem cell transplant in patients with B-cell lymphoma that does not respond to treatment (refractory) or has come back after a period of improvement (relapsed). Monoclonal antibodies, such as rituximab, can interfere with the ability of cancer cells to grow and spread. Giving rituximab before and after a donor peripheral blood stem cell transplant may help stop cancer from coming back and may help keep the patient's immune system from rejecting the donor's stem cells. |
Welcome to the RRID Resources search. From here you can search through a compilation of resources used by RRID and see how data is organized within our community.
You are currently on the Community Resources tab looking through categories and sources that RRID has compiled. You can navigate through those categories from here or change to a different tab to execute your search through. Each tab gives a different perspective on data.
If you have an account on RRID then you can log in from here to get additional features in RRID such as Collections, Saved Searches, and managing Resources.
Here is the search term that is being executed, you can type in anything you want to search for. Some tips to help searching:
If you are logged into RRID you can add data records to your collections to create custom spreadsheets across multiple sources of data.
Here are the facets that you can filter the data by.
If you have any further questions please check out our FAQs Page to ask questions and see our tutorials. Click this button to view this tutorial again.
